Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

  • Webcast Image Webcast
    X Q4 2018 Cytokinetics, Inc. Earnings Conference Call
    Feb 21, 2019 4:30 PM EST

    Q4 2018 Cytokinetics, Inc. Earnings Conference Call
    Feb 21, 2019 4:30 PM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

07/13/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Reports Fourth Quarter 2018 Financial Results
Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for GALACTIC-HF on Track for 1H 2019 Results from FORTITUDE-ALS Expected in Q2 2019 SOUTH SAN FRANCISCO, Calif. , Feb.
Toggle Summary Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF ( M ulticenter E xercise T olerance E valuation of O mecamtiv Mecarbil R elated to I
Toggle Summary Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Advancement of Second Novel Mechanism Cardiac Sarcomere Activator Reinforces Leadership Position in Muscle Directed Pharmacology SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first subject has been dosed in a Phase
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 21, 2019
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a

EVENTS

There are currently no events to display.